Summary
The use of topical steroids is associated with adverse systemic effects such as suppression of the hypothalamic-pituitary-adrenal (HPA) axis, and application of more than 50 g per week of clobetasol propionate cream has been shown to cause secondary adrenal failure. We describe 4 patients who used clobetasol propionate cream over a prolonged period; 3 patients used less than 50 g per week (7.5, 25 and 30 g per week) and yet all developed secondary adrenal failure for up to 4 months after cessation of therapy. Adrenal insufficiency following prolonged use of clobetasol propionate in moderate dosages may therefore be more common than previously recognized. It is suggested that the metyrapone test, which conveniently examines the entire HPA axis, should be employed in patients receiving long-term topical clobetasol propionate cream and that glucocorticoid supplementation should be given during episodes of stress, such as infections and surgery, for up to 4 months after cessation of therapy.
Introduction
The goal of topical glucocorticoid therapy is the delivery of a therapeutically effective dose of steroid to the target organ with the least possible systemic effects. The stratum corneum is usually designated as the barrier for drug absorption into the systemic circulation'. It is assumed that diseased skin has damaged barrier properties and that this can result in enhanced percutaneous absorption2. Removal of the horny layer increases the topical absorption of hydrocortisone four-fold3. The horny layer of the skin may also serve as a store from which drug penetration into the body continues for a period of days after a single application4. Therefore, small doses of potent topical steroids can have prolonged systemic effects such as suppression of the hypothalamic-pituitary-adrenal (HPA) axis. Some workers have noted normal or clinically insignificant partial suppression of the HPA axis responsiveness to stimulation during treatment with topical steroids' -. However, others reported sustained adrenal suppression following cessation of topical steroid treatment'0 -a state associated with an increased risk of acute adrenal insufficiency.
The variability of reported HPA axis status is a reflection of the heterogeneity of the patients and topical steroids studied and of methods of assessment used. This paper describes 4 patients treated with clobetasol propionate cream, seen during a three-year period, all of whom showed evidence of secondary adrenal failure using the metyrapone test to assess HPA activity.
Methods
The 4 patients were seen in the Dermatological Department at St Vincent's Hospital, Dublin, between July 1981 and July 1984.
Cortisol response to ACTH: Blood was drawn for measurement ofserum cortisol, and alpha-1-24 ACTH (tetracosactrin; Synacthen) 250 ug was administered intravenously. Blood was drawn for cortisol estimation one hour later. In response to Synacthen, cortisol levels should rise by at least 190 nmol/l, to at least 490 nmol/l. This procedure tests the ability of the adrenal to respond to exogenous ACTH ".
Metyrapone test: Metyrapone inhibits the final step in cortisol biosynthesis, the conversion of 11-deoxycortisol to cortisol. If the hypothalamus, the pituitary and adrenals are normally responsive to hypocortisolism, l1-deoxycortisol will accumulate in plasma. The metyrapone test therefore examines the responsiveness of the entire HPA axis"' .2 Metyrapone 30 mg/kg body weight was given orally at midnight with a snack. Blood was drawn for measurement of plasma 11-deoxycortisol and cortisol at 08.00 hours the following morning. Plasma 11-deoxycortisol of less than 175 nmol/l, while the plasma cortisol is suppressed to less than 200 nmol/l, is indicative of reduced hypothalamic-pituitary-adrenal function.
Case reports
Case 1: A 66-year-old woman with a 30-year history of psoriasis was referred because of a deterioration in her condition. She had been treated with various topical steroids for 10 years. During the 2 years prior to admission, she had applied 0.5% clobetasol propionate cream (Dermovate) in a dose of 25 g per week.
Her skin showed evidence of widespread psoriasis and other parts were atrophic, suggesting excessive use of topical steroids. Fasting serum cortisol was less than 55 nmol/I (normal 200-600 nmol/1). Four days later there was a blunted response to Synacthen (serum cortisol rose from 397 to 465 nmol/l). The metyrapone test was also abnormal (cortisol 91.9 nmol/l; 11-deoxycortisol 96 nmol/1). Her treatment was changed to a weaker steroid preparation and gradually phased out after 6 weeks. Emulsifying ointment was applied. Two months later her skin had improved and she was only using emulsifying ointment. The metyrapone test was still abnormal (cortisol 79.8 nmol/l; 11-deoxycortisol 139 nmol/l), suggesting suppression of the HPA axis despite six weeks without topical steroid use. Four months after the initial presentation her skin had become almost normal in texture and the psoriasis remained quiescent. Serum cortisol rose from 496 to 948 nmol/l in response to Synacthen. The response to metyrapone confirmed that the entire HPA axis had now returned to normal (cortisol 109 nmol/l; l1-deoxycortisol 193 nmol/l). Case 2: A 26-year-old woman was referred for severe atopic eczema. She had been treated intermittently with topical steroids since the age of two. During the 2 years prior to admission she had been using 0.5% clobetasol propionate cream 30 g per month.
On admission she had generalized eczema and a cushingoid appearance. The Synacthen test was normal, with cortisol levels increasing from 200 to 956 nmol/l, but the metyrapone test was abnormal (cortisol 110.9 nmol/l; 11-deoxycortisol 97 nmol/l). Her eczema was managed with decreasing concentrations of steroid cream and an emollient preparation. One month later her skin had improved but the eczema was still present on flexor surfaces. On these areas the patient was using 1% hydrocortisone cream. The metyrapone test was now normal (cortisol 133.9 nmol/l; 11-deoxycortisol 227 nmol/l).
Case 3:
A 39-year-old man was admitted to hospital for management of psoriasis which had been under treatment for 21 years. During the 5 years prior to admission he had been applying 0.05% clobetasol propionate cream daily and during the last 2 years used 100 g per week. On admission he had extensive psoriasis and cushingoid features. A basal serum cortisol was 55 nmol/l. Following Synacthen, serum cortisol rose from 55 to 94 nmol/l, a blunted response, while metyrapone administration was associated with low levels of cortisol, less than 55 nmol/l, and of 11-deoxycortisol, less than 7 nmol/l, showing a supression of the HPA axis. His psoriasis was managed with methotrexate, emulsifying ointment and 25 mg hydrocortisone orally daily. One month later basal serum cortisol was 74.8 nmol/l but 3 months after that the cortisol levels had risen to 208.2 nmol/l. Hydrocortisone was stopped. Eight months later the metyrapone test was normal (cortisol 112 nmol/l; 11-deoxycortisol 222 nmol/l). Case 4: A 55-year-old woman had been using 0.05% clobetasol propionate cream 30 g per week for 5 years to treat psoriasis. She showed cushingoid features with generalized psoriasis. Synacthen administration was associated with a subnormal serum cortisol response from 55 to 70.6 nmol/l. She was commenced on 25 mg hydrocortisone orally daily and her skin was managed with 1:4 diluted betamethasone valerate cream. One month after admission the morning cortisol was 518 nmol/l. The hydrocortisone was stopped and her psoriasis continued to be managed with mild topical steroids.
Discussion
Topical steroids can be divided into groups of 'strong', 'medium' and 'weak', depending on the clinical activity and ability to suppress the HPA axis'3. Clobetasol propionate should be-considered a 'very strong' topical medication'3. Cushing's syndrome, followed by secondary adrenal failure, has been reported in 4 patients using clobetasol propionate'4, who were applying substantial amounts of topical steroid (100-300 g per week). Allenby et al.'" studied the effects of clobetasol propionate on the HPA axis in 39 patients, and found that when more than 50 g per week of clobetasol propionate was applied to the skin, adrenal suppression was to be expected. It is of interest that 3 ofour 4 patients used less than50 g per week of clobetasol propionate cream (7.5, 25 and 30 grams per week). Therefore relatively small doses of clobetasol propionate cream may cause adverse systemic effects, with suppression of the HPA axis occurring more commonly than has previously been recognized.
Evaluation of patients suspected of secondary adrenal failure may consist of measuring basal cortisol, assessing the cortisol response to ACTH or hypoglycaemia, or measuring the HPA response to metyrapone'2. Basal plasma cortisol levels are of limited value, as normal or suppressed values are not exclusively seen in nornal adrenal function or adrenal failure respectively. Although a low plasma cortisol concentration in severely ill patients may be suggestive of adrenal insufficiency, it is necessary to establish that cortisol levels remain suppressed following an appropriate standard stimulation. The Synacthen test involves the administration of alpha-1-24 ACTH and tests the ability of the adrenals to respond to exogenous ACTH'3. Some patients with partial secondary adrenal failure respond normally to exogenous ACTH. We have previously shown that this may be particularly pertinent in patients who have recently received glucocorticoid therapy' 16* Therefore provocative tests that examine the entire HPA axis are necessary in assessing adrenal status following treatment with glucocorticoids. Metyrapone inhibits the final step in cortisol biosynthesis, the conversion of 11-deoxycortisol to cortisol. In subjects with normal function of the HPA axis, the resulting hypocortisolism induces increased secretion of ACTH, which results in accumulation of 11-deoxycortisol in plasma. The metyrapone test therefore examines the entire HPA axis""2 Furthermore, it yields similar information to that obtained from measuring the cortisol response to insulin-induced hypoglycaemia, but with the advantages of safety and convenience' 1. The superiority of the metyrapone test over the Synacthen test in detecting secondary adrenal failure was demonstrated in our Case 2, who had a normal response to exogenous ACTH while the metyrapone test demonstrated partial secondary adrenal failure. The metyrapone test is therefore recommended for the evaluation of patients treated with exogenous glucocorticoids such as topical steroids.
Our 4 patients had evidence of secondary adrenal failure following withdrawal of clobetasol propionate or considerable lowering of the dose, and the HPA axis activity returned towards normal after 1-4 months. We suggest that when topical clobetasol propionate is used chronically, it should be borne in mind that secondary adrenal failure is likely to occur even when small amounts (7.5 g per week) are used. Because of this, glucocorticoid supplementation should be used during episodes of stress, e.g. intercurrent infections and surgery, while topical treatment is ongoing or in the 4 months after treatment has been stopped. The systemic ill-effects of glucocorticoids must be borne in mind when deciding whether or not to introduce, or continue, their use.
